Treatment with Genetically Altered Viruses Targets and Destroys Ovarian Cancer in Mice
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
Brain Tumor Program Hosts Patient Education Event
The Smilow Brain Tumor Program hosted an educational seminar for patients and community providers discussing “A Thoughtful Approach in the Fight Against Brain Tumors: Personalizing Care for the Best Outcomes.” The event featured a welcome with hors d’oeuvres and time to mingle and was generously sponsored by the Lovemark Foundation and supported by the Connecticut Brain Tumor Alliance.
Genome analysis helps keep deadly brain cancer at bay for five years
An analysis of a patient’s deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.
What turns benign central nervous system tumors deadly
More than one in three tumors that affect the central nervous system are meningiomas and most are benign. However, some can turn deadly. In a new study, Yale researchers identified genetic abnormalities that mark atypical meningiomas, which have a 40% chance of recurring after surgical removal and are marked by a shorter survival rate than benign tumors.
Why doctors may keep a patient awake for brain surgery
A rare look at brain surgery with the patient alert and awake at Smilow Cancer Hospital at Yale-New Haven. Anthony Munoz has a brain tumor that is not cancerous. Neurosurgeon Dr. Jennifer Moliterno, who specializes in brain tumors, is focused on the massive one just above his left temple.Source: WTNH News Channel 8
How 14-year-old Haad Khwaja beat the odds to survive brain cancer
Fourteen-year-old Haad Khwaja moved from Pakistan to the United States, but an even more dramatic trip was his journey from diagnosis with a rare form of brain cancer to his successful treatment with an innovative program of highly targeted radiation at Yale Medicine.Source: Yale Medicine
Solving the mystery of meningiomas reveals a surprise twist
In solving one mystery — the genetic roots of benign brain tumors called meningiomas — a team of scientists led by Yale researchers stumbled upon an even greater one: How is it possible that two of the mutations linked to meningiomas occur in a gene crucial to all life?
Yale team tracks twists and turns on the road to malignancy
Gliomas can begin as benign growth in brain tissue but almost all eventually morph into malignant cancers called GBMs. Despite medical and surgical advances, GBMs remain one of the most deadly cancers in humans. In a comprehensive genomic study of gliomas that progressed into GBMs, an international team led by Yale Cancer Center researchers discovered the mechanisms that cause this transformation, findings that have implications about how the disease is treated.
New Drugs on the Horizon for Stroke and Hydrocephalus
Kristopher Kahle, MD, assistant professor of neurosurgery and of cellular and molecular physiology at Yale School of Medicine, recently published a study describing a new compound that could reduce swelling in the brain caused by stroke or hydrocephalus.
Molecular Control of Neurotransmitter Linked to Autism Described
In two new papers published Oct. 15 in Science Signaling, researchers from Yale, France, Japan, and the United Kingdom have zeroed in on a molecular mechanism crucial to normal brain development, which, when impaired, causes autism-like symptoms in mice.
Brain Hemorrhage Surgery Boosts Survival, but Disability Risk Still High
While patients who undergo surgery for intracerebral hemorrhage (ICH) survive at higher rates than those who do not receive surgery, they are also at high risk of significant disability, according to a new Yale-led study published in the journal JAMA.
The 3rd Critical Care and Emergency Neuroscience CME Course was held on May 24, 2018 at Yale West Campus.
The 3rd Critical Care and Emergency Neuroscience CME Course was held on May 24, 2018 at Yale West Campus. A collaboration between the Departments of Neurology and Neurosurgery, it attracted 180+ registered participants from across the state (and tri-state region). This year’s theme was Resuscitation of Severe and Traumatic Brain Injury (TBI).